EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Open Access · CC BY-NC-ND 4.0

The efficacy and safety of nanoparticle albumin bound‐paclitaxel‐based regimen as second‐ or third‐line treatment in patients with advanced esophageal squamous cell carcinoma

Dao Xin iD, Yan Song, Lan Mu, Bo Zhang iD, Ling Qi, Jing Gao, Xingyuan Wang, Jianping Xu, Tao Qu, Jing Huang iD

Thoracic Cancer · 2023

DOI: 10.1111/1759-7714.14885 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Thoracic Cancer, 2023. Verfasst von Dao Xin und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Scien…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Esophageal Squamous Cell Carcinoma, Lung Neoplasms, Esophageal Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

There are limited reports on nanoparticle albumin bound‐paclitaxel (nab‐paclitaxel) regimens as second‐ or third‐line treatments for advanced esophageal squamous cell carcinoma (ESCC). Additionally, its safety and efficacy in ESCC patients after failure of first‐line programmed cell death protein‐1 (PD‐1) blockade plus chemotherapy have not been reported. In this study, we aimed to assess the efficacy and tolerability of nab‐paclitaxel regimens as second‐ or later‐line treatment in advanced ESCC.

Methods

We retrospectively reviewed clinical data of advanced ESCC patients who participated in a randomized phase III clinical study and received serplulimab or placebo plus chemotherapy at our institution, and consecutive patients who received subsequent nab‐paclitaxel‐based regimens as second‐ or later‐line treatment were included for data collection and analysis.

Results

A total of 39 patients were included, 25 (64.1%) received serplulimab plus chemotherapy and 14 (35.9%) received chemotherapy alone as first‐line treatment. Treatment strategies included nab‐paclitaxel monotherapy (7/39, 17.9%), or in combination with other chemotherapy (19/39, 48.7%), with anti‐PD‐1 antibodies (12/39, 30.8%) or with nimotuzumab (1/39, 2.6%). Overall, the objective response rate (ORR) and disease control rate (DCR) were 33.3% (13/39) and 61.5% (24/39), respectively. With a median follow‐up of 9.7 months, the median progression‐free survival and median overall survival were 5.0 and 7.9 months, respectively. The most common adverse events were neuropathy peripheral (30.8%), anemia (30.8%), neutrophil count decreased (23.1%), and nausea (20.5%).

Conclusions

Nab‐paclitaxel‐based regimen could be a safe and effective option as second‐ or later‐line treatment in patients with advanced ESCC, regardless of their previous exposure to PD‐1 inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungEsophageal Squamous Cell CarcinomaLung NeoplasmsEsophageal NeoplasmsNanoparticlesHumansRetrospective StudiesPaclitaxelAlbuminsAntineoplastic Combined Chemotherapy Protocols

Stichwörter der Autor:innen

chemotherapyesophageal squamous cell carcinomaimmunotherapynanoparticle albumin bound-paclitaxel

Substanzen

130-nm albumin-bound paclitaxelPaclitaxelAlbumins

Autor:innen und Institutionen

  • Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Department of Oncology, Guizhou Provincial People's Hospital, Guiyang, China.

ORCID-Profile: Dao Xin, Bo Zhang, Jing Huang

Zitieren

APA

Xin, D., Song, Y., Mu, L., Zhang, B., Qi, L., Gao, J., Wang, X., Xu, J., Qu, T., & Huang, J. (2023). The efficacy and safety of nanoparticle albumin bound‐paclitaxel‐based regimen as second‐ or third‐line treatment in patients with advanced esophageal squamous cell carcinoma. Thoracic Cancer. https://doi.org/10.1111/1759-7714.14885

Vancouver

Xin D, Song Y, Mu L, Zhang B, Qi L, Gao J, et al. The efficacy and safety of nanoparticle albumin bound‐paclitaxel‐based regimen as second‐ or third‐line treatment in patients with advanced esophageal squamous cell carcinoma. Thoracic Cancer. 2023. doi:10.1111/1759-7714.14885

BibTeX
@article{Xin2023,
  author = {Xin, Dao and Song, Yan and Mu, Lan and Zhang, Bo and Qi, Ling and Gao, Jing and Wang, Xingyuan and Xu, Jianping and Qu, Tao and Huang, Jing},
  title = {The efficacy and safety of nanoparticle albumin bound‐paclitaxel‐based regimen as second‐ or third‐line treatment in patients with advanced esophageal squamous cell carcinoma},
  journal = {Thoracic Cancer},
  year = {2023},
  doi = {10.1111/1759-7714.14885}
}
Kostenlos starten →